[go: up one dir, main page]

WO2006086865A3 - Combi-preparation of nucleoside and non-nucleoside reverse transcriptase inhibitors for the treatment of hiv infections - Google Patents

Combi-preparation of nucleoside and non-nucleoside reverse transcriptase inhibitors for the treatment of hiv infections Download PDF

Info

Publication number
WO2006086865A3
WO2006086865A3 PCT/BR2006/000031 BR2006000031W WO2006086865A3 WO 2006086865 A3 WO2006086865 A3 WO 2006086865A3 BR 2006000031 W BR2006000031 W BR 2006000031W WO 2006086865 A3 WO2006086865 A3 WO 2006086865A3
Authority
WO
WIPO (PCT)
Prior art keywords
nucleoside
treatment
combi
preparation
reverse transcriptase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/BR2006/000031
Other languages
French (fr)
Other versions
WO2006086865A2 (en
Inventor
Maira Merces Barreto
Grace Gondin Rei Mafra
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fundacao Oswaldo Cruz
Original Assignee
Fundacao Oswaldo Cruz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacao Oswaldo Cruz filed Critical Fundacao Oswaldo Cruz
Publication of WO2006086865A2 publication Critical patent/WO2006086865A2/en
Publication of WO2006086865A3 publication Critical patent/WO2006086865A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention concerns a pharmaceutical composition comprising nevirapine, zidovudine and lamivudine in a single coated tablet. Furthermore, the invention concerns a process to prepare such a composition, the use of such a composition in the treatment of human immunodeficiency caused by HIV infection, and a method of treatment for human immunodeficienc .
PCT/BR2006/000031 2005-02-21 2006-02-21 Combi-preparation of nucleoside and non-nucleoside reverse transcriptase inhibitors for the treatment of hiv infections Ceased WO2006086865A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BRPI0500586-8A BRPI0500586A (en) 2005-02-21 2005-02-21 pharmaceutical composition, process for preparing said composition, use of the composition thereof in the treatment of immunodeficiency caused by HIV infection and method of treatment thereof
BRPI0500586-8 2005-02-21

Publications (2)

Publication Number Publication Date
WO2006086865A2 WO2006086865A2 (en) 2006-08-24
WO2006086865A3 true WO2006086865A3 (en) 2006-12-28

Family

ID=36916809

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/BR2006/000031 Ceased WO2006086865A2 (en) 2005-02-21 2006-02-21 Combi-preparation of nucleoside and non-nucleoside reverse transcriptase inhibitors for the treatment of hiv infections

Country Status (3)

Country Link
BR (1) BRPI0500586A (en)
RU (1) RU2007144541A (en)
WO (1) WO2006086865A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110117193A1 (en) * 2008-01-17 2011-05-19 Duquesne University Of The Holy Spirit Antiretroviral drug formulations for treatment of children exposed to hiv/aids

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200110500B (en) * 2001-05-11 2002-04-03 Cipla Medpro Pty Ltd Pharmaceutical composition.
US20020098242A1 (en) * 1997-07-31 2002-07-25 Darder Carlos Picornell Oral pharmaceutical preparation comprising an antiulcer activity compound, and process for its production
WO2004002498A1 (en) * 2002-06-27 2004-01-08 Glaxo Group Limited Antiviral regimens
WO2006001029A2 (en) * 2004-06-25 2006-01-05 Hetero Drugs Limited Antiretroviral compositions

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020098242A1 (en) * 1997-07-31 2002-07-25 Darder Carlos Picornell Oral pharmaceutical preparation comprising an antiulcer activity compound, and process for its production
ZA200110500B (en) * 2001-05-11 2002-04-03 Cipla Medpro Pty Ltd Pharmaceutical composition.
WO2004002498A1 (en) * 2002-06-27 2004-01-08 Glaxo Group Limited Antiviral regimens
WO2006001029A2 (en) * 2004-06-25 2006-01-05 Hetero Drugs Limited Antiretroviral compositions

Also Published As

Publication number Publication date
WO2006086865A2 (en) 2006-08-24
RU2007144541A (en) 2009-06-20
BRPI0500586A (en) 2006-10-10

Similar Documents

Publication Publication Date Title
MX2009013349A (en) Chemical compounds.
NO20091258L (en) Entantiomerically pure phosphoindoles as HIV inhibitors
WO2009055006A8 (en) Deuterated darunavir
WO2008127364A3 (en) Antiviral compounds and use thereof
NZ585226A (en) Inhibitors of human immunodeficiency virus replication
NO20070762L (en) Topical antiviral preparations
NO20081592L (en) Dipeptidyl peptidase inhibitors for the treatment of diabetes
WO2012039596A3 (en) Pharmaceutical compositions for calanolides, their derivatives and analogues, and process for producing the same
BRPI0820162A2 (en) compound, pharmaceutical composition, method for prophylaxis or treatment of HIV infection or for prophylaxis, treatment or delay in the onset of AIDS
WO2007068934A3 (en) Pharmaceutical combination comprising nucleotide and nucleoside reverse transcriptase inhibitors (such as tenofovir and lamivudine) in different parts of the dosage unit
WO2009062576A8 (en) Benzimidazoledihydrothiadiazinone derivatives as fructose-1,6-bisphosphatase inhibitors, and pharmaceutical compositions comprising same
AU2024259244A1 (en) CRYSTALLINE METHIONINE ADENOSYLTRANSFERASE 2a (MAT2A) INHIBITOR AND USES THEREOF
WO2006122003A3 (en) Diaryl-purine, azapurines and -deazapurines as non-nucleoside reverse transcriptase inhibitors for treatment of hiv
WO2008129501A3 (en) Pharmaceutical compositions of duloxetine
WO2006110831A3 (en) Method of inducing neutralizing antibodies to human immunodeficiency virus
NO20074780L (en) Heterocyclylamide-substituted imidazoles
WO2009126293A3 (en) Potent chimeric nrti-nnrti bifunctional inhibitors of hiv-1 reverse transcriptase
SG10201501376XA (en) Phosponate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production
WO2008033500A3 (en) Carbohydrate-based vaccines for hiv
WO2009015446A3 (en) Triazole derivatives as viral replication inhibitors
EP1848697A4 (en) Diketo acids with nucleobase scaffolds: anti-hiv replication inhibitors targeted at hiv integrase
WO2006086865A3 (en) Combi-preparation of nucleoside and non-nucleoside reverse transcriptase inhibitors for the treatment of hiv infections
UY29358A1 (en) THIAZOLIDINONES, ITS PREPARATION AND ITS USE AS A MEDICINAL PRODUCT
BRPI0509667A (en) Substituted azaquinazolines with antiviral efficacy
WO2007002172A3 (en) Hiv-1 protease inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: A200711687

Country of ref document: UA

ENP Entry into the national phase

Ref document number: 2007144541

Country of ref document: RU

Kind code of ref document: A

122 Ep: pct application non-entry in european phase

Ref document number: 06721591

Country of ref document: EP

Kind code of ref document: A2

WWW Wipo information: withdrawn in national office

Ref document number: 6721591

Country of ref document: EP